Item 5.02 Election of Director; Departure of Certain Officers; Appointment of


          Certain Officers; Compensatory Arrangement of Certain Officers.

On January 16, 2020, the Board of Directors of Q2Earth, Inc. ("Q2Earth" or the "Company") appointed Douglas R. Baum as a director of Q2Earth, effective immediately. Mr. Baum currently serves as a consultant to several drug development companies. From 2011 to January 2017 he served as President and CEO at Xeris Pharmaceuticals overseeing production of approvals through the FDA and capital raising.

Other than his appointment to the Q2Earth board during the past 5 years, Mr. Baum has not served on the board of directors of any company that was required to file reports pursuant to the Securities Exchange Act of 1934, as amended, or was a registered investment company under the Investment Company Act of 1940, as amended. Mr. Baum was granted a 5-year option to purchase 200,000 shares of the Company's commons stock exercisable at $0.02 per share. The options vest one-half in 12 months and the balance in 24 months.

The Company issued a Press Release announcing the appointment of Mr. Baum, copy of which is attached as Exhibit 99.1 and is incorporated by reference

Item 9.01 Financial Statements Pro Forma Financial Information and Exhibits.






    (d)       Exhibits

Exhibit No.   Description

99.1            Press Release issued by Q2Earth on January 16, 2020.

© Edgar Online, source Glimpses